BCR and lymphoma: Consistent with previous reports showing that BCR ablation does not lead to cell death in cMyc-driven lymphoma (Varano et al, 2017; He et al, 2018), we did not observe any significant differences in cell viability and proliferation between BCR-KO and wild-type (WT) cells (Fig 1C).